Actualités
Emploi

Publication le 07/10/2020

Le projet soutenu par la Fondation ARC vise à identifier à l’aide de Biomarqueurs une signature prédictive de réponse au blocage de l’axe PD-1/PD-L1 chez des patients atteints de cancers du poumon non à petites cellules en récidive ou métastatique en 2e ligne thérapeutique. Dans ce contexte, il est admis que la présence d’une réponse lymphocytaire T-CD8 anti-tumorale est associée à la réponse aux anti-PD-1/PD-L1. 
L’objectif primaire du projet cherchera  à comparer différents tests ((LT-CD8 résidents (TRM), LT-CD8 totaux, Signature IFN?, TMB et néoépitope, répertoire T) pouvant refléter une réponse anti-tumorale lymphocytaire T-CD8 pré-existante.
En objectif secondaire, on recherchera si l’analyse de ces biomarqueurs est comparable sur des biopsies récentes ou plus anciennes d’un même patient.
Le projet est porté par 5 équipes Inserm, l’équipe de BioInformatique et Biologie des Systèmes de l’IRCM de Montpellier à la charge de l’analyse des données cliniques.

En savoir plus
 

Publication : 17/09/2020

Description: Radiotherapy is one of the main treatments for solid tumors. Severe late radiation-induced toxicity of the surrounding normal tissues occurs in 5% to 10% of patients following radiotherapy. The radiation-induced lymphocyte apoptosis assay developed to predict late radiation-induced toxicity in patients has demonstrated to be significantly associated with toxicities. However, the molecular mechanism explaining the link between the lymphocyte apoptosis rate and the development of late toxicity is still unknown. It is well established that the acid sphingomyelinase/ceramide pathway is involved in radiation-induced apoptosis, more particularly in endothelial cells. We have started to look at this pathway in peripheral blood mononuclear cells (PBMC) in cancer patients. We observed ceramide expression in response to radiation in patients’ samples and we were able to identify an increase in acid sphingomyelinase activity at 8 Gy. This project proposes to study the ceramide pathways in PBMC responsiveness to ionizing radiation in cancer patients and the consequences on apoptosis, ROS and inflammation.

The goal of this project is to have a better understanding on the correlation between radiation-induced late toxicity and apoptosis and to help improve the life quality of the patients.

More

Publication : 02/09/2020

The NanoTumor consortium is a French national multi-disciplinary workforce that aims to study cancer initiation and progression at molecular and subcellular level, by combining cutting-edge technologies and expertise in electron and fluorescence 2D-3D imaging, spatial transcriptomics and mass-spectrometry, micropatterning and microfluidics/biomechanics in various cellular and animal models, anti-intrabody/PPI engineering, and high-throughput screening. It will explore several children and adults’ cancers characteristics from the structure of underlying molecular complexes, spatio-temporal genes and proteins expression patterns, all the way up to subcellular organization, tissues morphology/rheology, and ultimately drug design and screening.

To support the research program of WP3, a postdoc/engineer will be initially hired for 18 months with the objective of securing 18 additional months. The postdoc/engineer will be in charge of optimizing the experimental protocols required during the project, in particular immunochemistry, cell culture, live cell imaging techniques, and biochemistry. The postdoc/engineer will be also in charge of the formation of students (Masters, PhD) to these experimental approaches. Previous experience in NGS, proteomics, HTS, protein engineering, and/or bioinformatics would be a strong asset. The position will be located at the IRCM in Montpellier, but will require personal flexibility since the postdoc/engineer may be involved in experiments in all the laboratories of the consortium (stays from days to months).

More